Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Giorgio V. Scagliotti(Ospedale San Luigi Gonzaga), David R. Gandara(University of California, Davis), Mauro Zukin(Heidelberg University), Shehkar Patil(Heidelberg University), Joachim von Pawel(Asklepios Fachkliniken München-Gauting), Keunchil Park(The University of Texas MD Anderson Cancer Center), Janusz Rolski(Fundación Instituto Valenciano de Oncología), Piotr Serwatowski(Heidelberg University), Raghunadharao Digumarti(Heidelberg University), Jin S. Lee(Heidelberg University), Bonne Biesma(Heidelberg University), Anders Mellemgaard(AstraZeneca (United Kingdom)), U. Gatzemeier(Ontario Institute for Cancer Research), Tuncay Göksel(Heidelberg University), Lorinda Simms(Eli Lilly (United States)), Johan Vansteenkiste(KU Leuven), Purvish Parikh(Heidelberg University), Filippo de Marinis(Carlo Forlanini Hospital), Christian Manegold(Ontario Institute for Cancer Research), Katherine P. Sugarman(Heidelberg University)
Cited by 3,218
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k